Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients
Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.
With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival
June 3rd 2012Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.